Ppack (BioDeep_00000177902)

 

Secondary id: BioDeep_00000005012, BioDeep_00001870807

human metabolite blood metabolite


代谢物信息卡片


N-[1-Chloro-2-oxo-6-[(aminoiminomethyl)amino]hexane-3-yl]-1-(1-oxo-2-amino-3-phenylpropyl)pyrrolidine-2-carboxamide

化学式: C21H31ClN6O3 (450.21460460000003)
中文名称:
谱图信息: 最多检出来源 Mentha canadensis(plant) 54.39%

分子结构信息

SMILES: C1CC(N(C1)C(=O)C(CC2=CC=CC=C2)N)C(=O)NC(CCCN=C(N)N)C(=O)CCl
InChI: InChI=1S/C21H31ClN6O3/c22-13-18(29)16(8-4-10-26-21(24)25)27-19(30)17-9-5-11-28(17)20(31)15(23)12-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13,23H2,(H,27,30)(H4,24,25,26)

描述信息

同义名列表

12 个代谢物同义名

N-[1-Chloro-2-oxo-6-[(aminoiminomethyl)amino]hexane-3-yl]-1-(1-oxo-2-amino-3-phenylpropyl)pyrrolidine-2-carboxamide; 1-(2-amino-3-phenylpropanoyl)-N-{1-chloro-6-[(diaminomethylidene)amino]-2-oxohexan-3-yl}pyrrolidine-2-carboxamide; Phenylalanyl-prolyl-arginine-chloromethyl ketone; Phenylalanyl-prolyl-arginyl-chloromethane; D-Phe-pro-arg-chloromethyl ketone; D-Phe-Pro-Arg-CH2Cl; Phe-pro-arg-CH2-CL; Phe-pro-arg-CK; FPRMeCl; FPR-CMK; PPACK; FPRCK



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Marta Zarà, Ilaria Canobbio, Caterina Visconte, Jessica Canino, Mauro Torti, Gianni Francesco Guidetti. Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells. Cellular signalling. 2018 Aug; 48(?):45-53. doi: 10.1016/j.cellsig.2018.04.008. [PMID: 29705335]
  • Jeremy K Moore, Junjie Chen, Hua Pan, Joseph P Gaut, Sanjay Jain, Samuel A Wickline. Quantification of vascular damage in acute kidney injury with fluorine magnetic resonance imaging and spectroscopy. Magnetic resonance in medicine. 2018 06; 79(6):3144-3153. doi: 10.1002/mrm.26985. [PMID: 29148253]
  • Kentaro Takayama, Akihiro Taguchi, Fumika Yakushiji, Yoshio Hayashi. Identification of a degrading enzyme in human serum that hydrolyzes a C-terminal core sequence of neuromedin U. Biopolymers. 2016 Nov; 106(4):440-5. doi: 10.1002/bip.22770. [PMID: 26567043]
  • Rohun U Palekar, Chandu Vemuri, Jon N Marsh, Batool Arif, Samuel A Wickline. Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models. Journal of vascular surgery. 2016 Nov; 64(5):1459-1467. doi: 10.1016/j.jvs.2015.08.086. [PMID: 26482989]
  • Junjie Chen, Chandu Vemuri, Rohun U Palekar, Joseph P Gaut, Matthew Goette, Lingzhi Hu, Grace Cui, Huiying Zhang, Samuel A Wickline. Antithrombin nanoparticles improve kidney reperfusion and protect kidney function after ischemia-reperfusion injury. American journal of physiology. Renal physiology. 2015 Apr; 308(7):F765-73. doi: 10.1152/ajprenal.00457.2014. [PMID: 25651565]
  • Rohun U Palekar, Jacob W Myerson, Paul H Schlesinger, J Evan Sadler, Hua Pan, Samuel A Wickline. Thrombin-targeted liposomes establish a sustained localized anticlotting barrier against acute thrombosis. Molecular pharmaceutics. 2013 Nov; 10(11):4168-75. doi: 10.1021/mp400210q. [PMID: 24063304]
  • Manfred F Maitz, Claudia Sperling, Carsten Werner. Immobilization of the irreversible thrombin inhibitor D-Phe-Pro-Arg-chloromethylketone: a concept for hemocompatible surfaces?. Journal of biomedical materials research. Part A. 2010 Sep; 94(3):905-12. doi: 10.1002/jbm.a.32780. [PMID: 20730927]
  • Jonathan R Weinstein, Soyon Hong, John D Kulman, Caroline Bishop, Jon Kuniyoshi, Henrik Andersen, Bruce R Ransom, Uwe-Karsten Hanisch, Thomas Möller. Unraveling thrombin's true microglia-activating potential: markedly disparate profiles of pharmaceutical-grade and commercial-grade thrombin preparations. Journal of neurochemistry. 2005 Nov; 95(4):1177-87. doi: 10.1111/j.1471-4159.2005.03499.x. [PMID: 16271051]
  • T D Hewitson, M Martic, K J Kelynack, C N Pagel, E J Mackie, G J Becker. Thrombin is a pro-fibrotic factor for rat renal fibroblasts in vitro. Nephron. Experimental nephrology. 2005; 101(2):e42-9. doi: 10.1159/000086228. [PMID: 15942256]
  • Eeva-Maija Hietala, Paula Maasilta, Hanne Juuti, Juha-Pekka Nuutinen, Ari L J Harjula, Ulla-Stina Salminen, Riitta Lassila. Platelet deposition on stainless steel, spiral, and braided polylactide stents. A comparative study. Thrombosis and haemostasis. 2004 Dec; 92(6):1394-401. doi: 10.1160/th04-02-0124. [PMID: 15583749]
  • Ton Lisman, Jelle Adelmeijer, H Karel Nieuwenhuis, Philip G de Groot. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2003 Sep; 14(6):557-62. doi: 10.1097/00001721-200309000-00007. [PMID: 12960609]
  • Judith Leurs, Britt-Marie Wissing, Viveca Nerme, Katinka Schatteman, Petter Björquist, Dirk Hendriks. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thrombosis and haemostasis. 2003 Feb; 89(2):264-71. doi: 10.1055/s-0037-1613441. [PMID: 12574805]
  • Margaret L Rand, Joseph A Jakubowski, Matthew J Fisher, Amar Chahil, Raelene L Kinlough-Rathbone, Marian A Packham. Ethanol enhances the inhibitory effect of an oral GPIIb/IIIa antagonist on human platelet function. The Journal of laboratory and clinical medicine. 2002 Dec; 140(6):391-7. doi: 10.1067/mlc.2002.129311. [PMID: 12486406]
  • D J Kereiakes, T Lorenz, J J Young, G Kukielka, M N Mueller, L Nanniazzi-Alaimo, D R Phillips. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. Journal of thrombosis and thrombolysis. 2001 Oct; 12(2):123-7. doi: 10.1023/a:1012991303381. [PMID: 11729363]
  • T Sudo, H Ito, Y Ozeki, Y Kimura. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method. British journal of pharmacology. 2001 Aug; 133(8):1396-404. doi: 10.1038/sj.bjp.0704204. [PMID: 11498527]
  • B E Tardiff, L K Jennings, R A Harrington, D Gretler, R F Potthoff, D A Vorchheimer, P R Eisenberg, A M Lincoff, M Labinaz, D M Joseph, M F McDougal, N S Kleiman. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation. 2001 Jul; 104(4):399-405. doi: 10.1161/hc2901.093500. [PMID: 11468200]
  • M C Chang, C P Chan, H L Wu, R S Chen, W H Lan, Y J Chen, J H Jeng. Thrombin-stimulated growth, clustering, and collagen lattice contraction of human gingival fibroblasts is associated with its protease activity. Journal of periodontology. 2001 Mar; 72(3):303-13. doi: 10.1902/jop.2001.72.3.303. [PMID: 11327057]
  • E Gandossi, C Lunven, C N Berry. Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro. British journal of pharmacology. 2000 Mar; 129(5):1021-7. doi: 10.1038/sj.bjp.0703137. [PMID: 10696104]
  • S S Rebello, J Huang, J D Faul, B R Lucchesi. Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists. Journal of thrombosis and thrombolysis. 2000 Jan; 9(1):23-8. doi: 10.1023/a:1018679708251. [PMID: 10590185]
  • B Stouffer, S Habte, N Vachharajani, L Tay. Validation of an ELISA for the quantitation of lanoteplase, a novel plasminogen activator. Journal of immunoassay. 1999 Nov; 20(4):237-52. doi: 10.1080/01971529909349353. [PMID: 10595857]
  • M E Lyon, D W Drobot, S R Harding, A W Lyon. Evaluation of the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPACK) with the factor Xa inhibitor 1,5-dansyl-L-glutamyl-L-glycyl-L-arginine chloromethylketone (GGACK) as anticoagulants for critical care clinical chemistry specimens. Clinica chimica acta; international journal of clinical chemistry. 1999 Feb; 280(1-2):91-9. doi: 10.1016/s0009-8981(98)00176-4. [PMID: 10090527]
  • K Riesbeck, D Chen, G Kemball-Cook, J H McVey, A J George, E G Tuddenham, A Dorling, R I Lechler. Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis. Circulation. 1998 Dec; 98(24):2744-52. doi: 10.1161/01.cir.98.24.2744. [PMID: 9851962]
  • M Elg, D Gustafsson, J Deinum. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thrombosis and haemostasis. 1997 Oct; 78(4):1286-92. doi: 10.1055/s-0038-1657729. [PMID: 9364999]
  • D Prasa, L Svendsen, J Stürzebecher. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thrombosis and haemostasis. 1997 Mar; 77(3):498-503. doi: 10.1055/s-0038-1655996. [PMID: 9066001]
  • A W Lyon, S R Harding, D Drobot, M E Lyon. Use of thrombin inhibitors ex vivo allows critical care clinical chemistry and hematology testing on common specimens. Clinical biochemistry. 1997 Mar; 30(2):121-7. doi: 10.1016/s0009-9120(96)00158-0. [PMID: 9127693]
  • L Oltrona, P R Eisenberg, D R Abendschein, B G Rubin. Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts. Journal of vascular surgery. 1996 Oct; 24(4):624-31. doi: 10.1016/s0741-5214(96)70078-2. [PMID: 8911411]
  • S Zucker, C Conner, B I DiMassmo, H Ende, M Drews, M Seiki, W F Bahou. Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. The Journal of biological chemistry. 1995 Oct; 270(40):23730-8. doi: 10.1074/jbc.270.40.23730. [PMID: 7559545]
  • J L Baird, J A Raper. A serine proteinase involved in contact mediated repulsion of retinal growth cones by DRG neurites. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1995 Oct; 15(10):6605-18. doi: 10.1523/jneurosci.15-10-06605.1995. [PMID: 7472422]
  • M E Lyon, J S Fine, P J Henderson, A W Lyon. D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK): alternative anticoagulant to heparin salts for blood gas and electrolyte specimens. Clinical chemistry. 1995 Jul; 41(7):1038-41. doi: 10.1093/clinchem/41.7.1038. [PMID: 7600685]
  • D F Geffken, F G Keating, M H Kennedy, E S Cornell, E G Bovill, R P Tracy. The measurement of fibrinogen in population-based research. Studies on instrumentation and methodology. Archives of pathology & laboratory medicine. 1994 Nov; 118(11):1106-9. doi: NULL. [PMID: 7526817]
  • N Bangalore, W N Drohan, C L Orthner. High affinity binding sites for activated protein C and protein C on cultured human umbilical vein endothelial cells. Independent of protein S and distinct from known ligands. Thrombosis and haemostasis. 1994 Sep; 72(3):465-74. doi: 10.1055/s-0038-1648890. [PMID: 7855799]
  • S Hollenbach, U Sinha, P H Lin, K Needham, L Frey, T Hancock, A Wong, D Wolf. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. Thrombosis and haemostasis. 1994 Mar; 71(3):357-62. doi: 10.1055/s-0038-1642443. [PMID: 8029801]
  • H B Rahr, J V Sørensen, D Danielsen. Markers of coagulation and fibrinolysis in blood drawn into citrate with and without D-Phe-Pro-Arg-Chloromethylketone (PPACK). Thrombosis research. 1994 Mar; 73(5):279-84. doi: 10.1016/0049-3848(94)90024-8. [PMID: 8016814]
  • C R Falcon, M Cattaneo, A Ghidoni, P M Mannucci. The in vitro production of thromboxane B2 by platelets of diabetic patients is normal at physiological concentrations of ionized calcium. Thrombosis and haemostasis. 1993 Sep; 70(3):389-92. doi: 10.1055/s-0038-1649591. [PMID: 8259535]
  • E L Ball, K Dunlop, G R Matsueda. Selection of monoclonal antibodies that bind and inhibit tissue-type plasminogen activator. Hybridoma. 1993 Jun; 12(3):317-26. doi: 10.1089/hyb.1993.12.317. [PMID: 8359825]
  • A B Lumsden, A B Kelly, P A Schneider, W C Krupski, T Dodson, S R Hanson, L A Harker. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. Blood. 1993 Apr; 81(7):1762-70. doi: NULL. [PMID: 8461462]
  • F D Rubens, J I Weitz, J L Brash, R L Kinlough-Rathbone. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene. Thrombosis and haemostasis. 1993 Feb; 69(2):130-4. doi: . [PMID: 8456425]
  • S J Rogers, C W Pratt, H C Whinna, F C Church. Role of thrombin exosites in inhibition by heparin cofactor II. The Journal of biological chemistry. 1992 Feb; 267(6):3613-7. doi: NULL. [PMID: 1740413]
  • J M Ord, J Hasapes, A Daugherty, S R Thorpe, S R Bergmann, B E Sobel. Imaging of thrombi with tissue-type plasminogen activator rendered enzymatically inactive and conjugated to a residualizing label. Circulation. 1992 Jan; 85(1):288-97. doi: 10.1161/01.cir.85.1.288. [PMID: 1728459]
  • H Hoogendoorn, C H Toh, M E Nesheim, A R Giles. Alpha 2-macroglobulin binds and inhibits activated protein C. Blood. 1991 Nov; 78(9):2283-90. doi: NULL. [PMID: 1718493]
  • W C Horne, G M Anderson, D J Cohen. Reproducibility and temporal stability of ADP-induced platelet aggregation: comparison of the anticoagulants sodium citrate and D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone. American journal of hematology. 1991 Sep; 38(1):48-53. doi: 10.1002/ajh.2830380108. [PMID: 1897514]
  • H Hörmann, V Jelinić, H Richter. Cell-binding and internalization of soluble fibrin by platelets. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 1990 Oct; 1(4-5):547-9. doi: 10.1097/00001721-199010000-00036. [PMID: 2133233]
  • J I Weitz, M Hudoba, D Massel, J Maraganore, J Hirsh. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. The Journal of clinical investigation. 1990 Aug; 86(2):385-91. doi: 10.1172/jci114723. [PMID: 2384594]
  • M A Packham, N L Bryant, M A Guccione. Agglutination of rabbit platelets in plasma by the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Thrombosis and haemostasis. 1990 Apr; 63(2):282-5. doi: 10.1055/s-0038-1645210. [PMID: 2363129]
  • M L Rand, J Neiman, D M Jakowec, M A Packham. Effects of alcohol withdrawal on responses of platelets from alcoholics--a study using platelet-rich plasma from blood anticoagulated with D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (FPRCH2Cl). Thrombosis and haemostasis. 1990 Apr; 63(2):178-82. doi: 10.1055/s-0038-1645191. [PMID: 2363118]
  • K P Henrikson, E E Jazin, J A Greenwood, H W Dickerman. Prothrombin levels are increased in the estrogen-treated immature rat uterus. Endocrinology. 1990 Jan; 126(1):167-75. doi: 10.1210/endo-126-1-167. [PMID: 2293980]
  • W H Reinhart, A Haeberli, J Stark, P W Straub. Influence of blood withdrawal and anticoagulant on clotting activity, hematologic data, and certain rheologic measurements. The Journal of laboratory and clinical medicine. 1990 Jan; 115(1):98-103. doi: NULL. [PMID: 2105367]
  • A B Kelly, S R Hanson, L W Henderson, L A Harker. Prevention of heparin-resistant thrombotic occlusion of hollow-fiber hemodialyzers by synthetic antithrombin. The Journal of laboratory and clinical medicine. 1989 Oct; 114(4):411-8. doi: NULL. [PMID: 2794754]
  • C Lalau Keraly, R L Kinlough-Rathbone, M A Packham, H Suzuki, J F Mustard. Conditions affecting the responses of human platelets to epinephrine. Thrombosis and haemostasis. 1988 Oct; 60(2):209-16. doi: 10.1055/s-0038-1647031. [PMID: 3217918]
  • D C Stump, E J Topol, A B Chen, A Hopkins, D Collen. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator. Thrombosis and haemostasis. 1988 Apr; 59(2):133-7. doi: . [PMID: 2455358]
  • E Seifried, P Tanswell. Comparison of specific antibody, D-Phe-Pro-Arg-CH2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters. Thrombosis and haemostasis. 1987 Oct; 58(3):921-6. doi: . [PMID: 2448890]
  • M A Mohler, C J Refino, S A Chen, A B Chen, A J Hotchkiss. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thrombosis and haemostasis. 1986 Oct; 56(2):160-4. doi: 10.1055/s-0038-1661632. [PMID: 2433785]
  • P C Harpel, J W Fenton. Novel immunoenzyme assays for thrombin-antithrombin III and thrombin-alpha 2-macroglobulin complexes in plasma. Annals of the New York Academy of Sciences. 1986; 485(?):184-98. doi: 10.1111/j.1749-6632.1986.tb34580.x. [PMID: 2436524]
  • F A Ofosu, G J Modi, J Hirsh, M R Buchanan, M A Blajchman. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides. Annals of the New York Academy of Sciences. 1986; 485(?):41-55. doi: 10.1111/j.1749-6632.1986.tb34566.x. [PMID: 2436525]
  • B Ghebrehiwet, B P Randazzo, J T Dunn, M Silverberg, A P Kaplan. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. The Journal of clinical investigation. 1983 May; 71(5):1450-6. doi: 10.1172/jci110898. [PMID: 6304147]